The DOI matches its Crossref record, with a small difference in title or year; 47 of the 48 references it cites were found in a registry or an index.
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Open accessAbstract
BACKGROUND AND METHODS: Aldosterone is important in the pathophysiology of heart failure. In a doubleblind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was death from all causes. RESULTS: The trial was discontinued early, after a mean follow-up period of 24 months, because an interim analysis determined that spironolactone was efficacious. There were 386 deaths in the placebo group (46 percent) and 284 in the spironolactone group (35 percent; relative risk of death, 0.70; 95 percent confidence interval, 0.60 to 0.82; P<0.001). This 30 percent reduction in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from progressive heart failure and sudden death from cardiac causes. The frequency of hospitalization for worsening heart failure was 35 percent lower in the spironolactone group than in the placebo group (relative risk of hospitalization, 0.65; 95 percent confidence interval, 0.54 to 0.77; P<0.001). In addition, patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Association functional class (P<0.001). Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001). The incidence of serious hyperkalemia was minimal in both groups of patients. CONCLUSIONS: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Steroidal MRA, such as spironolactone and eplerenone, have established cardiovascular bene fi ts in those with heart failure and are useful for treating primary hyperaldosteronism and refractory hypertension.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [157]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Steroidal MRA are standard of care for treatment of heart failure (particularly with reduced ejection fraction) and primary hyperaldosteronism.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [157]
Experimental — accuracy not yet measuredIn the citing paper
“Steroidal MRA are useful for management of heart failure as well as primary hyperaldosteronism and resistant hypertension.32,33”
In the citing paper
“Beta-blockers are effective at reducing all-cause death and hospitalization for HF in patients with HFrEF, with or without diabetes.[509][510][511][512]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [509]
In the citing paper
“Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can also be effective antihypertensive agents (particularly for those with borderline or low potassium levels)89 and are important for morbidity and mortality reduction in patients with left ventricular dysfunction.90,91”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [91]
In the citing paper
“Many studies have reported the role of mineralocorticoid receptor blockers, such as spironolactone, not only in the treatment of hyperaldosteronism and resistant hypertension, but also in the prevention of metabolic and cardiovascular complications and cerebrovascular accidents in patients with normal values of aldosterone [17].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [17]
In the citing paper
“The mortality benefit of spironolactone in the RALES trial and eplerenone in the EMPHASIS-HF trial was consistent in T2DM and non-T2DM patients with HFrEF.158,159”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
Lechat, P. P., Brunhuber, K., Hofmann, R., Kuhn, P., Nesser, H., Slany, J., Weihs, W., Wiedermann, C. J., Wimmer, H., van Mieghem, W., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,922
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Swedberg, K. B., & KJEKSHUS, J. K. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Weber, K. T., & Brilla, C. G. (1991) · Circulation · doi:10.1161/01.cir.83.6.1849 · Cited by 2,035
Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure
Packer, M., O’Connor, C. M., Ghali, J. K., Pressler, M. L., Carson, P. E., Belkin, R. N., Miller, A. B., Neuberg, G. W., Frid, D. J., WERTHEIMER, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351504 · Cited by 1,194
Swedberg, K. B., Eneroth, P. H. E., KJEKSHUS, J. K., & Wilhelmsen, L. (1990) · Circulation · doi:10.1161/01.cir.82.5.1730 · Cited by 1,147
QT dispersion and sudden unexpected death in chronic heart failure
Barr, C. S., Naas, A. A. O., Freeman, M., Lang, C. C., & Struthers, A. D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91164-9 · Cited by 767
Remodeling of the rat right and left ventricles in experimental hypertension.
Brilla, C. G., Pick, R., Tan, L. B., Janicki, J. S., & Weber, K. T. (1990) · Circulation Research · doi:10.1161/01.res.67.6.1355 · Cited by 674
Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.
Dzau, V. J., Colucci, W. S., Hollenberg, N. K., & Williams, G. H. (1981) · Circulation · doi:10.1161/01.cir.63.3.645 · Cited by 532
(1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00465-1 · Cited by 493
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A. L., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 492
Brilla, C. G., Matsubara, L. S., & Weber, K. T. (1993) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1993.1066 · Cited by 427
Captopril in heart failure. A double blind controlled trial.
Cleland, J. G. F., Dargie, H. J., Hodsman, G. P., Ball, S. G., Robertson, J. I. S., Morton, J. J., East, B. W., Robertson, I., Murray, G. D., & Gillen, G. (1984) · Heart · doi:10.1136/hrt.52.5.530 · Cited by 379
Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials
Lakatos, E. (1988) · Biometrics · doi:10.2307/2531910 · Cited by 352
Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
Marc De Gasparo, B., Joss, U. R., Ramjoué, H.-P., Whitebread, S., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M., GROB, J., & Schmidlin, J. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22580-0 · Cited by 343
MacFadyen, R. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00091-6 · Cited by 340
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A. (1981) · Journal of Endocrinology · doi:10.1677/joe.0.0910457 · Cited by 339
The Management of Chronic Heart Failure
Cohn, J. N. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350707 · Cited by 328
Barr, C. S., Lang, C. C., Hanson, J., Arnott, M., Kennedy, N., & Struthers, A. D. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80353-1 · Cited by 318
Efficacy and tolerance of spironolactone in essential hypertension
Jeunemaı̂tre, X., Châtellier, G., Kreft-Jaïs, C., Charru, A., Devries, C., Plouin, P., Corvol, P. L., & Ménard, J. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)91030-7 · Cited by 271
Biollaz, J., Brunner, H. R., Gavras, I., Waeber, B., & Gavras, H. (1982) · PubMed · Cited by 238
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
Struthers, A. D. (1996) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(96)80009-1 · Cited by 228
Pitt, B. (1995) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00877755 · Cited by 207
Self-citationDuprez, D. A. (1998) · European Heart Journal · doi:10.1053/euhj.1998.1099 · Cited by 192
Antihypertensive Therapy with MK 4211
Biollaz, J., Brunner, H. R., Gavras, I., Waeber, B., & Gavras, H. P. (1982) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198211000-00014 · Cited by 190
Chronic administration of aldosterone depresses baroreceptor reflex function in the dog.
Wang, W. (1994) · Hypertension · doi:10.1161/01.hyp.24.5.571 · Cited by 162
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
Packer, M. (1997) · ACC Current Journal Review · doi:10.1016/s1062-1458(97)83279-5 · Cited by 158
Okubo, S., Niimura, F., Nishimura, H., Takemoto, F., Fogo, A. B., Matsusaka, T., & Ichikawa, I. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119249 · Cited by 154
Successes and failures of current treatment of heart failure
Cleland, J. G., Swedberg, K., & Poole-Wilson, P. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)90015-0 · Cited by 141
Borghi, C., Boschi, S., Ambrosioni, E., Melandri, G., Branzi, A., & Magnani, B. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03901.x · Cited by 140
Aldosterone and antialdosterone therapy in congestive heart failure
Weber, K. T., & Villarreal, D. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90238-8 · Cited by 108
Klug, D., Robert, V., & Swynghedauw, B. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90245-8 · Cited by 49
Angiotensin-converting enzyme inhibitor and spironolactone combination therapy
Zannad, F. M. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90243-6 · Cited by 39
Self-citationHajnóczky, G., Várnai, P., Holló, Z., Christensen, S. B., Balla, T., Enyedi, P., & Spät, A. (1991) · Endocrinology · doi:10.1210/endo-128-5-2639 · Cited by 28
High or low doses of ACE inhibitors for heart failure?
Hobbs, R. E. (1998) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.65.10.539 · Cited by 14
Szalay, K. S., Beck, M., Tóth, M., & de Châtel, R. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00150-7 · Cited by 14
Research works printed but not linked: 3
- 10.2307/2281868 · DOI · Paper page
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
- de Gasparo M, 1987, J Pharmacol Exp Ther, 240, 650
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
Self-citation2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Metadata
- Authors
- Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J.
- Affiliations
- University of Michigan (US)
- Cardiovascular Research Foundation (US)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Statistics Collaborative (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1999-09-02
- Volume
- 341
- Issue
- 10
- Pages
- 709-717
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2323458614
- Cited by
- 9,214
- References
- 48
- Citations by year
- 2026: 264 · 2025: 279 · 2024: 273 · 2023: 298 · 2022: 335 · 2021: 309 · 2020: 326 · 2019: 295 · 2018: 298 · 2017: 304 · 2016: 344 · 2015: 351 · 2014: 366 · 2013: 383 · 2012: 398
- FWCI
- 198.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Nephrology › Potassium and Related Disorders
- Keywords
- spironolactone, severe heart failure, aldosterone receptor blockade, mortality, hospitalization for worsening heart failure, sudden cardiac death, gynecomastia, hyperkalemia, NYHA functional class, ACE inhibitors, loop diuretics, digoxin
- MeSH terms
- Aged, Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Cause of Death, Diuretics, Double-Blind Method, Drug Therapy, Combination, Female, Gynecomastia, Heart Diseases, Heart Failure, Hospitalization, Humans, Hyperkalemia, Male, Middle Aged, Risk, Spironolactone, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
